Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double Blind, Placebo-controlled Study to Assess the Anti-viral Effect, Safety and Tolerability of Inhaled PC786 for the Treatment of Acute Respiratory Syncytial Virus (RSV) Infection in Adult Hematopoietic Stem Cell Transplant Recipients

Next Previous
Trial Profile

A Double Blind, Placebo-controlled Study to Assess the Anti-viral Effect, Safety and Tolerability of Inhaled PC786 for the Treatment of Acute Respiratory Syncytial Virus (RSV) Infection in Adult Hematopoietic Stem Cell Transplant Recipients

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Jan 2019

At a glance

  • Drugs PC-786 (Primary) ; Immunoglobulins; Ribavirin
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TreatRSV1
  • Sponsors Pulmocide

    • Most Recent Events

    • 09 Nov 2018 Status changed from not yet recruiting to recruiting.
    • 26 Oct 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top